Seeking Alpha

More on Novartis (NVS) Q4: Adjusted profit +3% to $3.1B. Net profit +74% to $2.05B, below...

More on Novartis (NVS) Q4: Adjusted profit +3% to $3.1B. Net profit +74% to $2.05B, below consensus of $2.38B. Last year was affected by writedowns. Pharmaceutical division sales flat at $8.3B, Diovan sales -25% to $992M after loss of patent protection. Shares +2.4% in Zurich.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs